To say this has been a big year for Summit Therapeutics (NASDAQ: SMMT) would be a huge understatement. The stock has risen ...

Bob Duggan, chairman and co-CEO of Summit Therapeutics Inc. (NASDAQ:SMMT), is capitalizing on a remarkable 689% stock surge ...

The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.

Summit Therapeutics (SMMT 7.20%) is an exciting stock for many investors as its shares are up by 158% in the last three ...

On Monday, Summit Therapeutics Inc (SMMT) stock saw a decline, ending the day at $20.5 which represents a decrease of $-0.71 or -3.35% from the prior close of $21.21. The stock opened at $21.16 and ...

We recently compiled a list of the 10 Best QQQ Stocks to Buy According to Analysts. In this article, we are going to take a ...

On Friday, Summit Therapeutics Inc (SMMT) stock saw a modest uptick, ending the day at $19.95 which represents a slight increase of $1.34 or 7.20% from the prior close of $18.61. The stock opened at ...

Handelsbanken Fonder AB boosted its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 37.7% in the third ...

Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical ...

Oncotelic's Cautionary Note on Forward-Looking Statements ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

The Boston-based startup is developing what executives hope will be more effective treatments for depression, anxiety, and ...